Incyte Corporation (BIT:1INCY)
Italy
· Delayed Price · Currency is EUR | Market Cap | 17.06B |
| Revenue (ttm) | 4.38B |
| Net Income (ttm) | 1.10B |
| Shares Out | n/a |
| EPS (ttm) | 5.46 |
| PE Ratio | 15.56 |
| Forward PE | 13.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 11 |
| Open | 85.56 |
| Previous Close | 85.56 |
| Day's Range | 85.56 - 85.56 |
| 52-Week Range | 47.33 - 96.00 |
| Beta | n/a |
| RSI | 49.31 |
| Earnings Date | Feb 10, 2026 |
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO fo... [Read more]
Financial Performance
In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.
Financial numbers in USD Financial StatementsNews
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is t...
Incyte Remains Undervalued As Opzelura And Niktimvo Scale
Incyte started 2026 on a high note. On January 7, its stock hit an all-time high of $112.29. In my view, the key drivers of raised investor interest in Incyte are the strong performance of its ruxolit...
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conferenc...
Baird Chautauqua International Growth Fund: Q4 2025 Winners, Laggards, Buys & Sells
Baird Chautauqua International Growth Fund underperformed its benchmark as stock selection in health care and consumer discretionary detracted most from relative returns. Fanuc reported September quar...
Incyte: Why The Market Is Overreacting To A Guidance 'Miss'
Incyte experienced an 8.2% sell-off after 2026 guidance appeared to miss consensus by $680M, but this was due to a royalties accounting nuance. Adjusted for royalties, INCY's 2026 sales guidance is ne...
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Incyte Corporation (INCY) Q4 2025 Earnings Call Transcript
Incyte weak 2026 revenue forecast heightens Jakafi patent concerns
Incyte forecast annual sales below Wall Street estimates on Tuesday with its key growth driver Opzelura expected to underperform, raising concerns about the drugmaker's ability to offset looming paten...
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Fourth Quarter and Full Year 2025 Financial Results.
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tue...
What Investors Should Know Before Buying Incyte
Incyte offers a compelling risk-adjusted return profile, outperforming healthcare benchmarks with robust growth and moderate volatility. INCY is successfully transitioning from Jakafi dependence to a ...
Incyte: Buy For The Turnaround, Stay For The Pipeline
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex...
Incyte's Pipeline Potential Signals Massive Upside For Investors
Incyte is a rare, profitable biotech with earnings doubling since 2021, driven by its core hematology franchise and rapidly expanding dermatology and oncology portfolios. INCY's non-Jakafi portfolio i...
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity
Bill Meury, Incyte president and CEO, joins 'Fast Money' to talk potential M&A, its growth trajectory, its product pipeline, and more.
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins
Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Mo...
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagn...
Incyte's blood cancer therapy meets main goal in late-stage trial
Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.
Best Defensive Stocks To Balance Tech Sector Volatility
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted ...
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The pre...